Funding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2025; Background: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, star...
Funding Information: This work was supported by Novartis Pharma AG. EuroSpA was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2024 The Author(s).; Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who h...
Funding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in r...
Funding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG . Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2023 The Author(s); This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decad...